Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
635 articoli
A landmark screen of approved kinase inhibitors reveals 94% of cancer mutations are already targetable — and uncovers surprising new drug uses.
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
A landmark genomic analysis of 50,000 tumors maps cancer-driving mutations across tumor types, revealing critical patterns that could reshape precision oncology.
A 13-year Italian cohort study finds ultra-processed foods don't raise breast cancer risk, but alcoholic beverages do.
Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.
A landmark RET-fusion lung cancer trial shows strong PFS gains but a puzzling OS signal — revealing a critical flaw in how crossover trials are designed.
A pooled analysis of 2.5 million people links higher BMI and waist size to bladder cancer risk — but only in males.
Updated phase II data show a 37-month median response duration for ASPS patients on atezolizumab, with fusion type predicting outcomes.
The ICARUS-LUNG01 trial sheds light on why some lung cancer patients respond to antibody-drug conjugates while others resist.
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
Peter Attia breaks down why prostate cancer deaths are rising despite available screening tools and how modern diagnostics can fix this.
